Comparison of patient demographics and clinical and molecular characteristics between RAEB and AML-LBC
| Characteristics . | RAEB (n = 47) . | AML-LBC (n = 29) . | P . |
|---|---|---|---|
| Age, years | .12 | ||
| Median | 66 | 61 | |
| Range | 31-81 | 30-84 | |
| Missing | 0 | 0 | |
| Sex | .32 | ||
| Male | 30 (64%) | 22 (76%) | |
| Female | 17 (36%) | 7 (24%) | |
| Missing | 0 | 0 | |
| WBC count (×109/L) | 1.40E-03 | ||
| Median | 5 | 14 | |
| Range | 1.1-109 | 1.4-127 | |
| ND | 0 | 0 | |
| Platelet count (×109/L) | .5 | ||
| Median | 70 | 71 | |
| Range | 9-740 | 7-260 | |
| ND | 0 | 0 | |
| BM blasts (%) | 3.10E-13 | ||
| Median | 11% | 25% | |
| Range | 1-19 | 20-29 | |
| ND | 0 | 0 | |
| Erythroblasts (%) | 21% | 12% | .061 |
| Range | 2-47 | 1-60 | |
| ND | 2 | 0 | |
| RS | 13 | 7 | 1 |
| ND | 1 | 1 | |
| SRSF2 | 8 (17%) | 7 (24.1%) | .073 |
| U2AF35 | 0 (0%) | 4 (13.8%) | |
| SF3B1 | 2 (4.26%) | 1 (3.45%) | |
| Total SF mutants | 10 (21.3%) | 12 (41.4%) | |
| FLT3ITD* | 1 (11.1%) | 0 (0%) | .47 |
| FLT3TKD* | 0 (0%) | 0 (0%) | 1 |
| NPM1+* | 0 (0%) | 2 (20%) | .47 |
| CEBPA double mutation* | 0 (0%) | 0 (0%) | 1 |
| CEBPA single mutation* | 1 (11.1%) | 1 (10%) | 1 |
| IDH1* | 0 (0%) | 2 (20%) | .47 |
| IDH2* | 1 (11.1%) | 0 (0%) | .47 |
| DNMT3A* | 0 (0%) | 4 (40%) | .1 |
| NRAS/KRAS* | 2 (22.2%) | 2 (20%) | 1 |
| ASXL1* | 0 (0%) | 1 (10%) | 1 |
| Characteristics . | RAEB (n = 47) . | AML-LBC (n = 29) . | P . |
|---|---|---|---|
| Age, years | .12 | ||
| Median | 66 | 61 | |
| Range | 31-81 | 30-84 | |
| Missing | 0 | 0 | |
| Sex | .32 | ||
| Male | 30 (64%) | 22 (76%) | |
| Female | 17 (36%) | 7 (24%) | |
| Missing | 0 | 0 | |
| WBC count (×109/L) | 1.40E-03 | ||
| Median | 5 | 14 | |
| Range | 1.1-109 | 1.4-127 | |
| ND | 0 | 0 | |
| Platelet count (×109/L) | .5 | ||
| Median | 70 | 71 | |
| Range | 9-740 | 7-260 | |
| ND | 0 | 0 | |
| BM blasts (%) | 3.10E-13 | ||
| Median | 11% | 25% | |
| Range | 1-19 | 20-29 | |
| ND | 0 | 0 | |
| Erythroblasts (%) | 21% | 12% | .061 |
| Range | 2-47 | 1-60 | |
| ND | 2 | 0 | |
| RS | 13 | 7 | 1 |
| ND | 1 | 1 | |
| SRSF2 | 8 (17%) | 7 (24.1%) | .073 |
| U2AF35 | 0 (0%) | 4 (13.8%) | |
| SF3B1 | 2 (4.26%) | 1 (3.45%) | |
| Total SF mutants | 10 (21.3%) | 12 (41.4%) | |
| FLT3ITD* | 1 (11.1%) | 0 (0%) | .47 |
| FLT3TKD* | 0 (0%) | 0 (0%) | 1 |
| NPM1+* | 0 (0%) | 2 (20%) | .47 |
| CEBPA double mutation* | 0 (0%) | 0 (0%) | 1 |
| CEBPA single mutation* | 1 (11.1%) | 1 (10%) | 1 |
| IDH1* | 0 (0%) | 2 (20%) | .47 |
| IDH2* | 1 (11.1%) | 0 (0%) | .47 |
| DNMT3A* | 0 (0%) | 4 (40%) | .1 |
| NRAS/KRAS* | 2 (22.2%) | 2 (20%) | 1 |
| ASXL1* | 0 (0%) | 1 (10%) | 1 |
Number of cases (percentage), median (range), or missing values depicted where appropriate. P values indicate the comparison between RAEB groups vs AML-LBC group.
ND, not determined;
Comparison of 9 RAEB vs 10 AML-LBC.